Review
Copyright ©The Author(s) 2022.
World J Diabetes. Sep 15, 2022; 13(9): 683-695
Published online Sep 15, 2022. doi: 10.4239/wjd.v13.i9.683
Figure 2
Figure 2 Simplified comparison between metabolic profiles with sodium-glucose cotransporter-2 inhibitors or dexamethasone. Metabolites with observed high serum levels appear in light green, metabolites with supposed increased serum levels appear in highlight green with white center, those with decreased serum levels in gray center, those with unchanged serum levels appear in light orange and finally, those which remain untested appear in white. Incomes with sodium-glucose cotransporter-2 inhibitors suggest utilization of Ketone bodies and ketogenic amino acids as reactive for Krebs cycle, and indirectly urea cycle, when utilization of glucose is decreased. On the other hand, administration of dexamethasone is associated with elevated rates of glucogenic amino acids or ketogenic-glucogenic amino acids, concurring to Krebs cycle and urea cycle activations. TCA: Tricarboxylic acid cycle; DXM: Dexamethasone.